|Classification and external resources|
A 4mL sample of hyperlipidemic blood with lipids separated into the top fraction. (Sample is in an EDTA collection tube.)
Hyperlipidemia, hyperlipoproteinemia, or hyperlipidaemia (British English) involves abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. It is the most common form of dyslipidemia (which includes any abnormal lipid levels).
Lipids (fat-soluble molecules) are transported in a protein capsule. The size of that capsule, or lipoprotein, determines its density. The lipoprotein density and type of apolipoproteins it contains determines the fate of the particle and its influence on metabolism.
Hyperlipidemias are divided in primary and secondary subtypes. Primary hyperlipidemia is usually due to genetic causes (such as a mutation in a receptor protein), while secondary hyperlipidemia arises due to other underlying causes such as diabetes. Lipid and lipoprotein abnormalities are common in the general population, and are regarded as a modifiable risk factor for cardiovascular disease due to their influence on atherosclerosis. In addition, some forms may predispose to acute pancreatitis.
- 1 Classification
- 2 Management
- 3 See also
- 4 References
- 5 External links
Hyperlipidemias may basically be classified as either familial (also called primary) caused by specific genetic abnormalities, or acquired (also called secondary) when resulting from another underlying disorder that leads to alterations in plasma lipid and lipoprotein metabolism. Also, hyperlipidemia may be idiopathic, that is, without known cause.
Hyperlipidemias are also classified according to which types of lipids are elevated, that is hypercholesterolemia, hypertriglyceridemia or both in combined hyperlipidemia. Elevated levels of Lipoprotein(a) may also be classified as a form of hyperlipidemia.
Familial hyperlipidemias are classified according to the Fredrickson classification which is based on the pattern of lipoproteins on electrophoresis or ultracentrifugation. It was later adopted by the World Health Organization (WHO). It does not directly account for HDL, and it does not distinguish among the different genes that may be partially responsible for some of these conditions.
|OMIM||Synonyms||Defect||Increased lipoprotein||Main symptoms||Treatment||Serum appearance||Estimated prevalence|
|Type I||a||238600||Buerger-Gruetz syndrome or familial hyperchylomicronemia||Decreased lipoprotein lipase (LPL)||Chylomicrons||Acute pancreatitis, lipemia retinalis, eruptive skin xanthomas, hepatosplenomegaly||Diet control||Creamy top layer||1 in 1,000,000|
|b||207750||Familial apoprotein CII deficiency||Altered ApoC2|
|c||118830||LPL inhibitor in blood|
|Type II||a||143890||Familial hypercholesterolemia||LDL receptor deficiency||LDL||Xanthelasma, arcus senilis, tendon xanthomas||Bile acid sequestrants, statins, niacin||Clear||1 in 500 for heterozygotes|
|b||144250||Familial combined hyperlipidemia||Decreased LDL receptor and increased ApoB||LDL and VLDL||Statins, niacin, fibrate||Clear||1 in 100|
|Type III||107741||Familial dysbetalipoproteinemia||Defect in Apo E 2 synthesis||IDL||Tubo-Eruptive Xanthomas & Palmar Xanthomas||Fibrate, statins||Turbid||1 in 10,000|
|Type IV||144600||Familial hypertriglyceridemia||Increased VLDL production and Decreased elimination||VLDL||Can cause pancreatitis at high triglyceride levels||Fibrate, niacin, statins||Turbid||1 in 100|
|Type V||144650||Increased VLDL production and Decreased LPL||VLDL and Chylomicrons||Niacin, fibrate||Creamy top layer & turbid bottom|
Hyperlipoproteinemia type I
Type I hyperlipoproteinemia exists in several forms:
- Lipoprotein lipase deficiency (Type Ia), due to a deficiency of lipoprotein lipase (LPL) or altered apolipoprotein C2, resulting in elevated chylomicrons, the particles that transfer fatty acids from the digestive tract to the liver.
- Familial apoprotein CII deficiency (Type Ib), a condition caused by a lack of lipoprotein lipase activator.:533
- Chylomicronemia due to circulating inhibitor of lipoprotein lipase (Type Ic)
Type I hyperlipoproteinemia usually presents in childhood with eruptive xanthomata and abdominal colic. Complications include retinal vein occlusion, acute pancreatitis, steatosis and organomegaly, and lipaemia retinalis.
Hyperlipoproteinemia type II
Hyperlipoproteinemia type II, by far the most common form, is further classified into type IIa and type IIb, depending mainly on whether there is elevation in the triglyceride level in addition to LDL cholesterol.
This may be sporadic (due to dietary factors), polygenic, or truly familial as a result of a mutation either in the LDL receptor gene on chromosome 19 (0.2% of the population) or the ApoB gene (0.2%). The familial form is characterized by tendon xanthoma, xanthelasma and premature cardiovascular disease. The incidence of this disease is about 1 in 500 for heterozygotes, and 1 in 1,000,000 for homozygotes.
HLPIIa is a rare genetic disorder characterized by increased levels of LDL cholesterol in the blood due to the lack of uptake (no Apo B receptors) of LDL particles. This pathology however is the second most common disorder of the various hyperlipoproteinemias, with individuals with a heterozygotic predisposition of 1 in every 500 and individuals with homozygotic predisposition of 1 in every million. These individuals may present with a very unique set of physical characteristics such as: Xanthelasma’s (yellow deposits of fat underneath the skin often presenting in the nasal portion of the eye), tendon and tuberous xanthomas, Arcus juvenilis (the graying of the eye often characterized in older individuals), Arterial bruits, claudication, and of course atherosclerosis. Lab findings for these individuals are obvious and yet interesting in the fact that their Serum cholesterol is 2-3 times greater than normal as well as increased LDL cholesterol but their triglycerides and VLDL values fall in the normal ranges. To manage person’s with HLPIIa drastic measures may need to be taken especially if their HDL cholesterol is less than 30 mg/dl and their LDL cholesterol is greater than 160 mg/dl. A proper diet for these individuals requires a decrease in total fat to less than 30% of total calories with a ratio of mon:poly:saturated fat of 1:1:1. Cholesterol should be reduced to less than 300 mg/day thus the avoidance of animal products and to increase fiber intake to more than 20g/day with 6g of soluble fiber/day. Of course exercise should be promoted as exercise can increase HDL. The overall prognosis for these individuals is in the worst case scenario if uncontrolled and untreated individuals may die before the age of 20, however if one seeks a prudent diet with correct medical intervention the individual my see an increased incidence of xanthomas with each decade, Achilles tendinitis will occur, and accelerated atherosclerosis.
The high VLDL levels are due to overproduction of substrates, including triglycerides, acetyl CoA, and an increase in B-100 synthesis. They may also be caused by the decreased clearance of LDL. Prevalence in the population is 10%.
- Familial combined hyperlipoproteinemia (FCH)
- Lysosomal acid lipase deficiency, often called (Cholesteryl ester storage disease)
- Secondary combined hyperlipoproteinemia (usually in the context of metabolic syndrome, for which it is a diagnostic criterion)
Hyperlipoproteinemia type III
This form is due to high chylomicrons and IDL (intermediate density lipoprotein). Also known as broad beta disease or dysbetalipoproteinemia, the most common cause for this form is the presence of ApoE E2/E2 genotype. It is due to cholesterol-rich VLDL (β-VLDL). Its prevalence has been estimated to be approximately 1 in 10,000.
It is associated with hypercholesterolaemia (typically 8-12 mmol/L), hypertriglyceridaemia (typically 5-20 mmol/L), a normal ApoB concentration, and two types of skin signs (palmar xanthomata or orange discoloration of skin creases, and tuberoeruptive xanthomata on the elbows and knees). It is characterized by the early onset of cardiovascular disease and peripheral vascular disease. Remnant hyperlipidaemia occurs as a result of abnormal function of the ApoE receptor, which is normally required for clearance of chylomicron remnants and IDL from the circulation. The receptor defect causes levels of chylomicron remnants and IDL to be higher than normal in the blood stream. The receptor defect is an autosomal recessive mutation or polymorphism.
Hyperlipoproteinemia type IV
Hyperlipoproteinemia type V
It is also associated with glucose intolerance and hyperuricemia
In medicine, combined hyperlipidemia (or -aemia) (also known as "Multiple-type hyperlipoproteinemia") is a commonly occurring form of hypercholesterolemia (elevated cholesterol levels) characterised by increased LDL and triglyceride concentrations, often accompanied by decreased HDL.:534 On lipoprotein electrophoresis (a test now rarely performed) it shows as a hyperlipoproteinemia type IIB. It is the most common inherited lipid disorder, occurring in approximately one in two hundred persons. In fact, almost one in five individuals who develop coronary heart disease before the age of sixty will have this disorder. The elevated triglyceride levels (>5 mmol/l) are generally due to an increase in VLDL (very low density lipoprotein), a class of lipoprotein that is prone to cause atherosclerosis.
- Familial combined hyperlipidemia (FCH) is the familial occurrence of this disorder, probably caused by decreased LDL receptor and increased ApoB.
- Acquired combined hyperlipidemia is extremely common in patients who suffer from other diseases from the metabolic syndrome ("syndrome X", incorporating diabetes mellitus type II, hypertension, central obesity and CH). Excessive free fatty acid production by various tissues leads to increased VLDL synthesis by the liver. Initially, most VLDL is converted into LDL until this mechanism is saturated, after which VLDL levels elevate.
Both conditions are treated with fibrate drugs, which act on the peroxisome proliferator-activated receptors (PPARs), specifically PPARα, to decrease free fatty acid production. Statin drugs, especially the synthetic statins (atorvastatin and rosuvastatin) can decrease LDL levels by increasing hepatic reuptake of LDL due to increased LDL-receptor expression.
Unclassified familial forms
Non-classified forms are extremely rare:
Acquired hyperlipidemias (also called secondary dyslipoproteinemias) often mimic primary forms of hyperlipidemia and can have similar consequences. They may result in increased risk of premature atherosclerosis or, when associated with marked hypertriglyceridemia, may lead to pancreatitis and other complications of the chylomicronemia syndrome. The most common causes of acquired hyperlipidemia are:
Other conditions leading to acquired hyperlipidemia include:
- renal failure
- nephrotic syndrome
- alcohol usage
- Some rare endocrine disorders and metabolic disorders
Treatment of the underlying condition, when possible, or discontinuation of the offending drugs usually leads to an improvement in the hyperlipidemia. Specific lipid-lowering therapy may be required in certain circumstances.
Another acquired cause of hyperlipidemia, although not always included in this category, is postprandial hyperlipidemia, a normal increase following ingestion of food
|This section requires expansion. (March 2009)|
For treatment of type II, dietary modification is the initial approach but many patients require treatment with statins (HMG-CoA reductase inhibitors) to reduce cardiovascular risk. If the triglyceride level is markedly raised, fibrates may be preferable due to their beneficial effects. Combination treatment of statins and fibrates, while highly effective, causes a markedly increased risk of myopathy and rhabdomyolysis and is therefore only done under close supervision. Other agents commonly added to statins are ezetimibe, niacin and bile acid sequestrants. Dietary supplementation with fish oil is also used to reduce elevated triglycerides, with the greatest effect occurring in patients with the greatest severity. There is some evidence for benefit of plant sterol-containing products and ω3-fatty acids
For the other types see the treatment column in the Fredrickson classification table above.
- thefreedictionary.com > hyperlipidemia Citing:
- Dorland's Medical Dictionary for Health Consumers. 2007 by Saunders, an imprint of Elsevier
- The American Heritage Medical Dictionary. 2007, 2004 by Houghton Mifflin Company.
- Chait A, Brunzell JD (June 1990). "Acquired hyperlipidemia (secondary dyslipoproteinemias)". Endocrinol. Metab. Clin. North Am. 19 (2): 259–78. PMID 2192873.
- Fredrickson, DS; Lees, RS (1965). "A system for phenotyping hyperlipoproteinemia" (PDF). Circulation 31 (3): 321–7. doi:10.1161/01.CIR.31.3.321. PMID 14262568.
- Hyperlipoproteinemia, Type I from Centre for Arab Genomic Studies. Retrieved July 2011. Citing: "About 1:1,000,000 people are affected with Hyperlipoproteinemia type I worldwide with a higher prevalence in some regions of Canada."
- Fung, M.; Hill, J.; Cook, D.; Frohlich, J. (2011). "Case series of type III hyperlipoproteinemia in children". Case Reports 2011: bcr0220113895. doi:10.1136/bcr.02.2011.3895.
- New Product Bulletin on Crestor® (rosuvastatin)
- OMIM entry 207750 last updated 02/10/2009
- Yamamura, T.; Sudo, H.; Ishikawa, K.; Yamamoto, A. (1979). "Familial type I hyperlipoproteinemia caused by apolipoprotein C-II deficiency". Atherosclerosis 34 (1): 53–65. doi:10.1016/0021-9150(79)90106-0. PMID 227429.
- James, William D.; Berger, Timothy G.; et al. (2006). Andrews' Diseases of the Skin: clinical Dermatology. Saunders Elsevier. ISBN 0-7216-2921-0.
- OMIM entry 118830 updated 03/18/2004
- Boman H,Hazzard WR, AlbersJJ, et ah Frequency of monogenic forms of hyperlipidemia in a normal population. AmJ ttum Genet 27:19A,1975. 
- "Medical Definition Search For 'Type 5 Hyperlipidemia". medilexicon. Retrieved 1 November 2013.
- thefreedictionary.com > hyperlipidemia Citing:
- Saunders Comprehensive Veterinary Dictionary, 3 ed. 2007 by Elsevier
- Mattar M, Obeid O. Fish oil and the management of hypertriglyceridemia. Nutr Health. 2009;20(1):41-9.
- Thompson, GR (2004). "Management of dyslipidaemia". Heart (British Cardiac Society) 90 (8): 949–55. doi:10.1136/hrt.2003.021287. PMC 1768388. PMID 15253984.